Patents Assigned to Legend Biotech USA Inc.
-
Publication number: 20250000977Abstract: Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.Type: ApplicationFiled: April 18, 2024Publication date: January 2, 2025Applicants: LEGEND BIOTECH USA INC., JANSSEN BIOTECH, INC.Inventors: Nitin PATEL, Lida PACAUD, Yuhong QIU, Nikoletta LENDVAI, William DERAEDT, Jordan Mark SCHECTER, Ana Rute DE ASCENSAO SLAUGHTER, Carolina LONARDI
-
Publication number: 20240409654Abstract: The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: ApplicationFiled: August 28, 2024Publication date: December 12, 2024Applicant: LEGEND BIOTECH USA INC.Inventors: Xiaohu FAN, Qiuchuan ZHUANG, Pingyan WANG, Lin WANG, Lei YANG, Jiaying HAO, Dan ZHAO, Xian HE
-
Publication number: 20240358754Abstract: Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.Type: ApplicationFiled: February 29, 2024Publication date: October 31, 2024Applicants: LEGEND BIOTECH USA INC., JANSSEN BIOTECH, INC.Inventors: Nitin PATEL, Lida PACAUD, Yuhong QIU, Nikoletta LENDVAI, William DERAEDT, Jordan Mark SCHECTER, Ana Rute DE ASCENSAO SLAUGHTER, Carolina LONARDI
-
Publication number: 20240156962Abstract: A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.Type: ApplicationFiled: November 1, 2023Publication date: May 16, 2024Applicants: LEGEND BIOTECH USA INC., JANSSEN BIOTECH, INC.Inventors: Lida PACAUD, Muhammad AKRAM, Dong GENG, Jordan SCHECTER, Carolyn Chang JACKSON, Enrique ZUDAIRE UBANI, Deepu MADDURI
-
Publication number: 20230270786Abstract: Provided herein are methods of treating a subject who has multiple myeloma with a ciltacabtagene autoleucel suspension. Also provided are pharmaceutical products containing ciltacabtagene autoleucel suspensions, instructions for use of the ciltacabtagene autoleucel suspensions, and methods for selling a drug product containing ciltacabtagene autoleucel suspensions.Type: ApplicationFiled: February 27, 2023Publication date: August 31, 2023Applicants: JANSSEN BIOTECH, INC., NANJING LEGEND BIOTECH CO., LTD., LEGEND BIOTECH USA INC.Inventors: Xiaohu FAN, Jordan SCHECTER, Lida PACAUD, Michael HIRSCHMANN
-
Patent number: 11535677Abstract: Provided herein are single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) having the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: GrantFiled: August 10, 2017Date of Patent: December 27, 2022Assignee: LEGEND BIOTECH USA INC.Inventors: Xiaohu Fan, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao, Dan Zhao, Xian He
-
Publication number: 20220127371Abstract: The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: ApplicationFiled: November 3, 2021Publication date: April 28, 2022Applicant: Legend Biotech USA Inc.Inventors: Xiaohu FAN, Qiuchuan ZHUANG, Pingyan WANG, Lin WANG, Lei YANG, Jiaying HAO, Dan ZHAO, Xian HE
-
Patent number: 11186647Abstract: The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: GrantFiled: February 4, 2021Date of Patent: November 30, 2021Assignee: LEGEND BIOTECH USA INC.Inventors: Xiaohu Fan, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao
-
Publication number: 20210261675Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: ApplicationFiled: February 1, 2021Publication date: August 26, 2021Applicant: Legend Biotech USA Inc.Inventors: Xiaohu FAN, Chuan-Chu CHOU, Qiuchuan ZHUANG, Pingyan WANG, Lin WANG, Lei YANG, Jiaying HAO
-
Publication number: 20210163615Abstract: The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: ApplicationFiled: February 4, 2021Publication date: June 3, 2021Applicant: Legend Biotech USA Inc.Inventors: Xiaohu FAN, Qiuchuan ZHUANG, Pingyan WANG, Lin WANG, Lei YANG, Jiaying HAO, Dan ZHAO, Xian HE
-
Patent number: 10934363Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: GrantFiled: August 10, 2016Date of Patent: March 2, 2021Assignee: Legend Biotech USA Inc.Inventors: Xiaohu Fan, Chuan-Chu Chou, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao